Weight & metabolic health
- The upstream driver
Visceral fat and insulin resistance drive the whole atherogenic pattern — high triglycerides, low HDL, small dense LDL, high ApoB. Losing visceral fat improves all of them, and even modest loss helps. GLP-1 drugs (semaglutide, tirzepatide) improve the metabolic profile, and SELECT showed semaglutide cut cardiovascular events ~20% in overweight patients without diabetes — a genuine new lever (though only partly via weight). None of this is a licence to skip proven LDL-lowering. Evidence ●●●●○